Production and Purification of Polyclonal Antibodies Against Recombinant BoNT/A-HcC Domain for Sandwich ELISA Detection of BoNT/A Detection of BoNT/A by Sandwich ELISA
Iranian Journal of Pharmaceutical Sciences,
Vol. 20 No. 1 (2024),
15 January 2024
,
Page 22-34
https://doi.org/10.22037/ijps.v20i1.44123
Abstract
Botulinum neurotoxin (BoNT), a lethal bacterial toxin causing neuroparalytic disease, necessitates robust detection methods to prevent and manage botulism outbreaks. The receptor-binding domain of the toxin's heavy chain (Hc) has been extensively explored as a potential BoNT vaccine candidate. This study's primary goal is the swift detection of Botulinum neurotoxin type A (BoNT/A) using a sandwich ELISA method employing polyclonal antibodies. The recombinant BoNT/A-285HcC was induced with one mM IPTG at 25°C for 18 hours to reduce inclusion bodies and purified using Ni-NTA under non-denaturing conditions. Immunization of animals followed a specific regimen using purified BoNT/A-285HcC recombinant antigen and Freund's adjuvant. IgG antibodies from immunized mice serum were isolated using protein G resin. The purified antibodies' reactivity with recombinant BoNT/A-285HcC protein was assessed through western blotting. Efficient protein expression was achieved, yielding 50 mg/L. The recombinant BoNT/A-285HcC, with a molecular weight of 46 kDa, was purified with a near 90% purity level. ELISA results demonstrated a significant rise in anti-BoNT/A antibody titers following three doses. Western blot analysis confirmed the specific binding capability of the purified anti-BoNT/A IgG. Ultimately, the sandwich ELISA developed in this study exhibited the ability to detect 100 pg/ml of BoNT/A, utilizing 1.25 µg/ml of mice antibody as the capture and 0.3 µg/ml of rabbit antibody as the detection antibody. Purified polyclonal antibodies against recombinant BoNT/A-285HcC can be effectively employed in diagnostic serological tests for BoNT/A detection, with a limit of detection (LOD) of 100 pg/ml, significantly enhancing our ability to combat BoNT-related threats and ensuring the safety of medical applications.
- Clostridium botulinum
- Botulinum neurotoxin type A
- Recombinant protein
- Sandwich ELISA
How to Cite
References
Sobel J. Botulism. Beyond anthrax: the weaponization of infectious diseases (2009) 85-105.
Anniballi F, Lonati D, Fiore A, Auricchio B, De Medici D, and Locatelli C A. New targets in the search for preventive and therapeutic agents for botulism. Expert Review of Anti-infective Therapy (2014) 12 (9): 1075-1086.
Zhang J-C, Sun L, and Nie Q-H. Botulism, where are we now? Clinical toxicology (2010) 48 (9): 867-879.
Hill K K and Smith T J. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Botulinum neurotoxins (2013) 1-20.
Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol (2012) 15 (3): 325-36.
Hobbs R J, Thomas C A, Halliwell J, and Gwenin C D. Rapid Detection of Botulinum Neurotoxins-A Review. Toxins (Basel) (2019) 11 (7).
Administration F a D. BAM Chapter 17: Clostridium botulinum.
https://www.fda.gov/food/laboratory-methods-food/bam-chapter-17-clostridium-botulinum
Pellett S et al. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes. mBio (2018) 9 (2).
Gardner A P and Barbieri J T. Light Chain Diversity among the Botulinum Neurotoxins. Toxins (Basel) (2018) 10 (7).
Gu S and Jin R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol (2013) 364 (21-44).
Matsui T et al. Structural basis of the pH-dependent assembly of a botulinum neurotoxin complex. J Mol Biol (2014) 426 (22): 3773-3782.
Rawson A M, Dempster A W, Humphreys C M, and Minton N P. Pathogenicity and virulence of Clostridium botulinum. Virulence (2023) 14 (1).
Hill K K and Smith T J. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol (2013) 364 (1-20).
Webb R et al. Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF). Toxicon (2020) 176 (67-76).
White D M, Pellett S, Jensen M A, Tepp W H, Johnson E A, and Arnason B G. Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect Immun (2011) 79 (8).
Webb R P et al. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins (Basel) (2017) 9 (9).
Schein C H and Noteborn M H M. Formation of Soluble Recombinant Proteins in Escherichia Coli is Favored by Lower Growth Temperature. Bio/Technology (1988) 6 (3).
Mühlmann M, Forsten E, Noack S, and Büchs J. Optimizing recombinant protein expression via automated induction profiling in microtiter plates at different temperatures. Microbial Cell Factories (2017) 16 (1).
Kielkopf C L, Bauer W, and Urbatsch I L. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis of Proteins. Cold Spring Harb Protoc (2021) 2021 (12).
Singh S M and Panda A K. Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng (2005) 99 (4).
Spriestersbach A, Kubicek J, Schäfer F, Block H, and Maertens B. Purification of His-Tagged Proteins. Methods Enzymol (2015) 559 (1-15).
Greenfield E A. Standard Immunization of Mice, Rats, and Hamsters. Cold Spring Harb Protoc (2020) 2020 (3).
Fishman J B and Berg E A. Protein A and Protein G Purification of Antibodies. Cold Spring Harb Protoc (2019) 2019 (1).
Tabatabaei M S and Ahmed M. Enzyme-Linked Immunosorbent Assay (ELISA). Methods Mol Biol (2022) 2508 (115-134).
Sule R, Rivera G, and Gomes A V. Western blotting (immunoblotting): history, theory, uses, protocol and problems. Biotechniques (2023) 75 (3).
Field M et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins (Basel) (2018) 10 (12).
Janik E, Ceremuga M, Saluk-Bijak J, and Bijak M. Biological Toxins as the Potential Tools for Bioterrorism. Int J Mol Sci (2019) 20 (5).
Capek P and Dickerson T J. Sensing the deadliest toxin: technologies for botulinum neurotoxin detection. Toxins (Basel) (2010) 2 (1): 24-53.
Thirunavukkarasu N et al. Botulinum Neurotoxin Detection Methods for Public Health Response and Surveillance. Front Bioeng Biotechnol (2018) 6 (80).
Bremer P T, Adler M, Phung C H, Singh A K, and Janda K D. Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays. J Med Chem (2017) 60 (1): 338-348.
Worbs S et al. Qualitative and Quantitative Detection of Botulinum Neurotoxins from Complex Matrices: Results of the First International Proficiency Test. Toxins (Basel) (2015) 7 (12): 4935-66.
Rasetti-Escargueil C and Popoff M R. Recent Developments in Botulinum Neurotoxins Detection. Microorganisms (2022) 10 (5): 1001.
Cheng L W and Stanker L H. Detection of botulinum neurotoxin serotypes A and B using a chemiluminescent versus electrochemiluminescent immunoassay in food and serum. J Agric Food Chem (2013) 61 (3): 755-60.
Ben David A, Torgeman A, Barnea A, and Zichel R. Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate. Protein Expr Purif (2015) 110 (122-9).
Ben David A, Diamant E, Barnea A, Rosen O, Torgeman A, and Zichel R. The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo. Clin Vaccine Immunol (2013) 20 (8): 1266-73.
Samiei Abianeh H, Nazarian S, Amani J, Rezaei A, Rostami M, and Ramezani M R. Immunogenicity Evaluation of a Recombinant C-terminus of Botulinum Neurotoxin Type A Binding Domain Protein. Journal of Applied Biotechnology Reports (2023) 10 (2): 1000-1008.
Samiei Abianeh H, Nazarian S, and Amani J. Expression, Purification and evaluation of the Immunogenicity of RecombinantC-terminus of the Receptor-Binding Domain of Neurotoxin Botulinum Protein Type B (BoNT/B-HcC). Scientific Journal of Kurdistan University of Medical Sciences (2023) 28 (3): 13-23.
Yu Y-Z et al. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Clinical Immunology (2010) 137 (2): 271-280.
Yu Y-Z, Sun Z-W, Wang S, and Yu W-Y. High-level Expression of the Hc Domain of Clostridium botulinum Neurotoxin Serotype A in Escherichia coli and Its Immunogenicity as an Antigen. Chinese Journal of Biotechnology (2007) 23 (5): 812-817.
Chen R et al. Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain. Protein Expression and Purification (2010) 71 (1): 79-84.
Paraskevopoulou V and Falcone F H. Polyionic Tags as Enhancers of Protein Solubility in Recombinant Protein Expression. Microorganisms (2018) 6 (2).
Feng L, Wang X, and Jin H. Rabbit monoclonal antibody: potential application in cancer therapy. Am J Transl Res (2011) 3 (3): 269-74.
Stanker L H, Merrill P, Scotcher M C, and Cheng L W. Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA. J Immunol Methods (2008) 336 (1): 1-8.
Chiao D J, Wey J J, and Tang S S. Monoclonal antibody-based enzyme immunoassay for detection of botulinum neurotoxin type A. Hybridoma (Larchmt) (2008) 27 (1).
Samiei Abianeh H, Nazarian S, and Amani J. Detection of Clostridium botulinum toxin type B by Sandwich ELISA method. Modares Journal of Biotechnology (2023) 13 (2): 133-146.
- Abstract Viewed: 463 times
- IJPS_Volume20_Issue1_Pages22-34 Downloaded: 265 times